Suzetrigine: Is it the new weapon of multimodal analgesia?
Abstract
ABSTRACT: Background: The opioid crisis remains one of the most pressing public health challenges worldwide. The risks of misuse, addiction, and overdose associated with opioids have led clinicians and researchers to pursue safer alternatives for acute pain management. Suzetrigine (VX-548), recently approved by the U.S. FDA, is a novel non-opioid analgesic that selectively inhibits the NaV1.8 sodium channel, offering a new peripheral mechanism for pain control. Objective: To summarize the current evidence on the pharmacological properties, clinical efficacy, safety profile, and challenges related to the use of Suzetrigine in acute pain treatment. Content: Suzetrigine binds specifically to the voltage-sensing domain 2 (VSD2) of NaV1.8, inhibiting sodium influx and neuronal excitability. It exhibits high plasma protein binding, extensive tissue distribution, and a pharmacokinetic profile supporting twice-daily dosing. Clinical trials have shown statistically significant pain reduction following abdominoplasty and bunionectomy compared to placebo, though not powered to establish superiority over opioids. Adverse events were mild and non-opioid-like. Limitations include its high cost, uncertain role in chronic pain, and limited long-term data. Observational studies suggest its utility in multimodal analgesia, particularly among opioid-naive patients or those with opioid use disorder. Conclusions: Suzetrigine is a promising addition to the multimodal analgesic arsenal. Its…
Read the paper
Related studies
- Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min
- De Novo Transcriptome Analysis and Detection of Antimicrobial Peptides of the American Cockroach Periplaneta americana (Linnaeus)
- Molecular Characterization and Expression Profiling of Tomato GRF Transcription Factor Family Genes in Response to Abiotic Stresses and Phytohormones
- Assembly of Tight Junction Strands: Claudin-10b and Claudin-3 Form Homo Tetrameric Building Blocks that Polymerise in a Channel-Independent Manner
- Update of the Pompe variant database for the prediction of clinical phenotypes: Novel disease‐associated variants, common sequence variants, and results from newborn screening
- Machine Learning-Based SERS Chemical Space for Two-Way Prediction of Structures and Spectra of Untrained Molecules
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.